Navigation Links
So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market
Date:11/15/2007

Hoffmann-La Roche Inc. CEO George Abercrombie, Pfizer R&D Head Martin Mackay, HHS Deputy Secretary Tevi Troy, Former CMS Administrator & FDA Commissioner Mark McClellan Headline Agenda at FDA/CMS Summit 2007

WASHINGTON, Nov. 15 /PRNewswire-USNewswire/ -- It's shaping up to be a record year for drug approvals. Unfortunately for the biopharma sector and investors, it's a record low. The Food and Drug Administration is on track to grant marketing approval to 18 or fewer new drugs in 2007, and pipelines are not looking better in the coming years. For the research and development and marketing executives responsible for getting new drugs to customers, the level of unpredictability may be unprecedented. And Washington lawmakers and regulators are driving the uncertainty. Yesterday's blockbuster will not be the prototype for future drug development. Sweeping new legislation is reforming the FDA and changing how drugs are developed; Medicare is radically altering product economics; and Wall Street is looking for the next big thing.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071115/DC07546LOGO )

The FDA/CMS Summit, taking place December 6-7 in Washington, D.C., will feature the key decision makers from government and industry to help biopharmaceutical executives understand what regulatory and policy developments mean for research and commercial success.

"Today may look a lot like yesterday, but the rules of the game have fundamentally changed," said Cole Werble, editor-in-chief of The RPM Report, the lead sponsor of the conference. "Industry needs to learn what recent changes to FDA law mean and what the impact might hold for drug development and marketing. The FDA/CMS Summit provides leaders in industry key insight from policy-makers who have been involved in these changes."

The FDA/CMS Summit provides health care executives with an exclusive oppo
'/>"/>

SOURCE Windhover Information Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
3. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
4. Stem Cell Science Holds Opportunities as Important Tool for Diabetes Research Beyond Cell-Based Treatments
5. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
6. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
8. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
9. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 A paper published today, ... portfolio " in Science Translational Medicine, ... to reduce the risk associated with investing in ... new levels of funding for developing so-called "orphan" ... unique collaboration between scientists at the National Center ...
(Date:2/27/2015)... Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced the addition ... to their offering. , Global Market Report ... Trypsin globally and regionally ( Europe , ... Latin America etc.). It captures Trypsin ... report focuses on three primary areas; manufacture methods & technology ...
(Date:2/27/2015)... February 27, 2015 Immunovaccine Inc. ... immunotherapy company, today announced that the U.S. Food ... Fast Track designation and Phase I clinical trials ... with the mutual co-development agreement signed with Gilead ... Track designation for the DPX-Survivac. , “We have ...
(Date:2/27/2015)... February 27, 2015 The fully ... (Nexera UC) can sequentially analyze up to 48 ... with high-sensitivity detection of targets by mass spectrometry. ... to fulfill the measurement requirements of a wide ... products, drug delivery and search for disease biomarkers, ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Global Market Report of Trypsin 2014-2018 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
... ROCKVILLE, Md., Oct. 3 Human Genome Sciences,Inc. (Nasdaq: ... the JMP,Securities Healthcare Focus Conference will be webcast and ... http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ), A member of Human Genome Sciences, ... October 6, 2008 at 10:30 AM Eastern Time., ...
... Cepheid (Nasdaq:,CPHD) today announced that it will report financial ... on Tuesday, October 28, 2008 after,the close of the ... at 2 p.m. Pacific Time,on Tuesday, October 28, 2008 ... visit Cepheid,s website at http://www.cepheid.com/investors ,at least 15 ...
... 3 /Xinhua-PRNewswire-FirstCall/ --,Pharmaceutical company Pharmaxis (ASX: PXS, NASDAQ: ... from its respiratory disease,program at the 2008 European ... the 4th to the 8th October. The ERS ... and clinicians to hear latest,advances in clinical diagnosis ...
Cached Biology Technology:Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast 2Pharmaxis Research Programs Highlighted at European Respiratory Society Congress 2Pharmaxis Research Programs Highlighted at European Respiratory Society Congress 3
(Date:2/25/2015)... Ark. , Feb. 25, 2015  ABC ... and billing in the Health and Fitness Industry, ... well as to MYiCLUBonline.  The latest upgrade includes ... the inclusion of cardless check-in via Identity One ... the first time through interactive displays at the ...
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:2/24/2015)... 2015 This report analyzes the worldwide markets for Face ... Biometrics, and Voice Biometrics. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific , ... , and Latin America . Annual estimates and ... seven-year historic analysis is provided for these markets. Market data and ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16
... are natural filters that help remove and transform pollutants ... human activities. Scientists know this as a result of ... dirty, at least very wet -- monitoring streams nationwide. ... reduces the potential for eutrophication the excessive growth ...
... streams play a major role in minimizing the amount ... downstream. This ecosystem service is valuable; excess nitrogen degrades ... depleting the water of oxygen. This phenomenon, also known ... This week, a team of scientists that included Cary ...
... used the occasion of the dedication of the Robert J. ... 1604 Campus to announce an $822,000 gift from the charitable ... we have wanted to create a lasting tribute to the ... ago, we asked the Board of Regents of the University ...
Cached Biology News:Streams natural filters, if not overloaded 2Small streams mitigate human influence on coastal ecosystems 2UTSA receives $822,000 from Kleberg Foundation to enhance scientific research 2
Fast, sensitive quantitation of Mouse IgM concentration....
Request Info...
... IgG FITC is used as the ... on tissues or culture cells where ... rabbits. It is highly recommended that ... the primary antibody, be included in ...
1000X solution used for inducing CopyControl™ based vectors to high copy numbers...
Biology Products: